Ebola viruses (EBOVs) are responsible for repeated outbreaks of fatal infections, including the recent deadly epidemic in West Africa. There are currently no approved therapeutic drugs or vaccines for the disease. EBOV has a membrane envelope decorated by trimers of a glycoprotein (GP, cleaved by furin to form GP1 and GP2 subunits), which is solely responsible for host cell attachment, endosomal entry and membrane fusion1,2,3,4,5,6,7. GP is thus a primary target for the development of antiviral drugs. Here we report the first, to our knowledge, unliganded structure of EBOV GP, and high-resolution complexes of GP with the anticancer drug toremifene and the painkiller ibuprofen. The high-resolution apo structure gives a more complete and accurate picture of the molecule, and allows conformational changes introduced by antibody and receptor binding to be deciphered8,9,10. Unexpectedly, both toremifene and ibuprofen bind in a cavity between the attachment (GP1) and fusion (GP2) subunits at the entrance to a large tunnel that links with equivalent tunnels from the other monomers of the trimer at the three-fold axis. Protein–drug interactions with both GP1 and GP2 are predominately hydrophobic. Residues lining the binding site are highly conserved among filoviruses except Marburg virus (MARV), suggesting that MARV may not bind these drugs. Thermal shift assays show up to a 14 °C decrease in the protein melting temperature after toremifene binding, while ibuprofen has only a marginal effect and is a less potent inhibitor. These results suggest that inhibitor binding destabilizes GP and triggers premature release of GP2, thereby preventing fusion between the viral and endosome membranes. Thus, these complex structures reveal the mechanism of inhibition and may guide the development of more powerful anti-EBOV drugs.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Takada, A. et al. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl Acad. Sci. USA 94, 14764–14769 (1997)
Hacke, M. et al. Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol. Nat. Commun. 6, 7688 (2015)
Aleksandrowicz, P. et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204 (suppl. 3), S957–S967 (2011)
Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340–343 (2011)
Côté, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344–348 (2011)
Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010)
Saeed, M. F., Kolokoltsov, A. A., Albrecht, T. & Davey, R. A. Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6, e1001110 (2010)
Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177–182 (2008)
Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164, 258–268 (2016)
Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424–1427 (2011)
World Health Organization. Ebola Situation Reports ; http://www.who.int/csr/disease/ebola/situation-reports/en/ (2016)
Veljkovic, V. et al. In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res . 4, 104 (2015)
Edwards, M. R. et al. High-throughput minigenome system for identifying small-molecule inhibitors of Ebola virus replication. ACS Infect. Dis. 1, 380–387 (2015)
Johansen, L. M. et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5, 190ra79 (2013)
Johansen, L. M. et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7, 290ra89 (2015)
Kouznetsova, J. et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg. Microbes Infect. 3, e84 (2014)
Lea, W. A. & Simeonov, A. Differential scanning fluorometry signatures as indicators of enzyme inhibitor mode of action: case study of glutathione S-transferase. PLoS One 7, e36219 (2012)
Cimmperman, P. et al. A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys. J. 95, 3222–3231 (2008)
Cheng, H. et al. Inhibition of Ebola and Marburg virus entry by G protein-coupled receptor antagonists. J. Virol. 89, 9932–9938 (2015)
Brecher, M. et al. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 86, 364–372 (2012)
Zhao, Y., Ren, J., Harlos, K. & Stuart, D. I. Structure of glycosylated NPC1 luminal domain C reveals insights into NPC2 and Ebola virus interactions. FEBS Lett. 590, 605–612 (2016)
Jeffers, S. A., Sanders, D. A. & Sanchez, A. Covalent modifications of the ebola virus glycoprotein. J. Virol. 76, 12463–12472 (2002)
Weissenhorn, W., Carfí, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605–616 (1998)
Gregory, S. M. et al. Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc. Natl Acad. Sci. USA 108, 11211–11216 (2011)
Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection. Cell 164, 392–405 (2016)
Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643–1645 (2005)
Dube, D. et al. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 83, 2883–2891 (2009)
Hood, C. L. et al. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J. Virol. 84, 2972–2982 (2010)
Schornberg, K. et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80, 4174–4178 (2006)
Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904–912 (2015)
Zhao, Y., Ren, J., Padilla-Parra, S., Fry, E. E. & Stuart, D. I. Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor. Nat. Commun. 5, 4321 (2014)
Desai, T. M. et al. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 10, e1004048 (2014)
Cavrois, M., De Noronha, C. & Greene, W. C. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20, 1151–1154 (2002)
Jones, D. M. & Padilla-Parra, S. Imaging real-time HIV-1 virion fusion with FRET-based biosensors. Sci. Rep. 5, 13449 (2015)
Walter, T. S. et al. A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta Crystallogr. D 61, 651–657 (2005)
Winter, G., Lobley, C. M. & Prince, S. M. Decision making in xia2. Acta Crystallogr. D 69, 1260–1273 (2013)
Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D 66, 22–25 (2010)
Winn, M. D., Murshudov, G. N. & Papiz, M. Z. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374, 300–321 (2003)
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004)
Stuart, D. I., Levine, M., Muirhead, H. & Stammers, D. K. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. J. Mol. Biol. 134, 109–142 (1979)
DeLano, W. L. & Lam, J. W. PyMOL: A communications tool for computational models. Abstr. Pap. Am. Chem. Soc . 230, U1371–U1372 (2005)
We thank Diamond scientists at I02 and I03 for assistance with data collection, T. S. Walter for help with crystallization and thermal-shift essay. Y.Z. was supported by the Biostruct-X project (283570) funded by the EU seventh Framework Programme (FP7), J.R. by the Wellcome Trust, and D.I.S., E.E.F. and K.H. by the UK Medical Research Council (MR/N00065X/1). This is a contribution from the UK Instruct Centre. The Wellcome Trust Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). A.Z. is supported by a Marie Curie Fellowship (658363), T.A.B. is supported by the MRC (MR/L009528/1). SP-P is funded by a Nuffield Department of Medicine Leadership Fellowship. D.I.S. is a Jenner Investigator.
D.I.S., T.A.B. and A.Z. are listed as inventors on the International Patent Application No. PCT/GB2016/050321 ‘Filovirus therapy’.
Reviewer Information Nature thanks E. Saphire, W. Weissenhorn and the other anonymous reviewer(s) for their contribution to the peer review of this work.
Extended data figures and tables
Representative thermal melt curves of EBOV GP with 10 μM compounds and 2% DMSO. a–d, Melting curves of EBOV GP with toremifene, ibuprofen or protein alone at pH 5.0, 6.0, 7.0 and 8.0, respectively. e, Small effects of SERM inhibitors tamoxifen, 4-hydroxytamoxifen and raloxifen on the melting temperature of EBOV GP shown at pH 5.2. f, Melt curves of EBOV GP with diaglycerol kinase inhibitor, anastrozole and benztropine mesylate at pH 5.2. g, h, Shifts in melting temperature (∆Tm °C in absolute value) were plotted against different concentrations of toremifene (g) or ibuprofen (h) at pH 5.2. Data are mean ± s.d. (n = 4). The affinity constant Kd is calculated by a ligand binding 1:1 saturation fitting with the SigmaPlot version 13 (Systat Software Inc.).
a, Scheme showing the structural organization of EBOV GP. FL, fusion loop; NHR and CHR, N- and C-terminal heptad repeats; SP, signal peptide; TM, transmembrane helix. The GPΔ construct used for structure determination is made by deleting residues 313–463 of the GP mucin domain and residues 633–676. Residue 312 is directly linked to 464. A foldon trimerization peptide and a 6× His tag are added at the C terminus. b, The GP2 trimer in the prefusion state (current structure). The trimer is shown as cartoon representation with the monomers coloured in red, green and blue, respectively. Disulfide bonds are shown as orange sticks. c, The six-helix bundle of GP2 in the post-fusion state.
a, The fusion loop that connects β19 and β20 of GP2 projects onto a shallow depression on the surface of a neighbouring monomer. The fusion loop is shown as a red coil with side chains drawn as grey sticks, the neighbouring monomer is shown in semi-transparent surface representation. b, Comparison of the fusion loop in the apo GP (red and grey) obtained at pH 5.2 with that in the KZ52 Fab complex (cyan) obtained at pH 8.3.
a, The several small pockets and three large tunnels in the GP trimer shown as grey surfaces. Protein backbones are drawn as ribbons and coloured as in Fig. 2 of the main text. A toremifene is bound at the entrance of each large tunnel and shown as yellow sticks. b, Close up view of a tunnel. Each tunnel is bordered by secondary structure elements from two neighbouring monomers.
a, The DFF lid (residues 192–194, blue coil for main chain and sticks for side chains) nestles at the entrance of the large tunnel in the apo structure. The rest of the protein is shown as an electrostatic surface. The putative cathepsin cleavage site at residue 190 is indicated by an arrow. b, c, Toremifene (yellow sticks in b) and ibuprofen (cyan sticks in c) bind at the same site by expelling the DFF lid. In both panels, the inhibitor bound structure is shown in blue (GP1) and red (GP2), the apo GP in grey. d, Comparing the binding modes of toremifene and ibuprofen. The toremifene-bound structure is shown in blue and red, the ibuprofen bound structure in grey.
The surfaces of α1′ and α1 helices, which undergo large conformational changes upon receptor binding, are protected by the 287–293 loop from the glycan cap domain and the N563 glycan from GP2 in the apo GP. The glycan is modelled as Man9GlcNAc2.
a, b, The chemical structures of toremifene (a) and ibuprofen (b). c, d, |Fo − Fc| omit electron density maps for toremifene (c) and ibuprofen (d) contoured at 3σ.
Amino acid sequence alignment of 7 filovirus GPs around the inhibitor-binding site. The amino acids that form contacts with toremifene or ibuprofen are coloured in green. Numbering corresponds to the full length Zaire EBOV GP, conserved residues are shown in a red background. Secondary structure elements are labelled on the top.
a, CCF2-loaded TZM-bl cells were exposed to EBOV pseudoparticles (EBOVpp) or control particles lacking envelope proteins (NoENV) at 4 °C to synchronise binding and receptor engagement before fusion was initiated by shifting cells to 37 °C in the presence of toremefine (15 μM and 1.5 μM), ibuprofen (150 μM and 15 μM), or just the solvent (5% DMSO). After 2 h incubation, cells were loaded with the CCF2-AM FRET biosensor, fixed and the ratio of blue (440–480 nm, cleaved CCF2-AM) to green (500–540 nm, uncleaved CCF2-AM) fluorescence measured. Cells are pseudocoloured according to this ratio: blue represents no fusion, red represents fusion. Scale bar: 80 μm. b, The percentage of fusogenic cells (red versus blue) was calculated taking the average max value coming from the negative control as a threshold for fusion, data are means ± s.d. (n = 10). *P ≤ 0.05, ***P ≤ 0.001 (unpaired t-test, compared to the EBOV plus DMSO control). ns, not significant (P > 0.05). Error bars represent s.d.
About this article
Cite this article
Zhao, Y., Ren, J., Harlos, K. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169–172 (2016). https://doi.org/10.1038/nature18615
A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment
Journal of Evidence-Based Integrative Medicine (2021)
Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target
Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses
Antiviral Research (2021)
Expert Opinion on Investigational Drugs (2021)
Bioorganic Chemistry (2021)